Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis (Q33424769)

26 July 2017

title

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis (English)

1 reference

metastatic renal cell carcinoma

26 July 2017

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

Matteo Santoni

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

Amelia Altavilla

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

author name string

S Bracarda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

R Iacovelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

L Boni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

M Rizzo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

L Derosa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

M Rossi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

L Galli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

M Sisani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

F Longo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

F Morelli

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

G Di Lorenzo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

C Porta

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

A Camerini

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

B Escudier

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

Rainbow Group

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

publication date

27 July 2015

1 reference

26 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

15 June 2020

page(s)

2107-2113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26216384 AND SRC:MED&resulttype=core&format=json

Sunitinib in patients with metastatic renal cell carcinoma

15 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Optimal management of metastatic renal cell carcinoma: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

Clinical biomarkers of response in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315

From randomized controlled trials to observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDV315